Women under the age of 40 account for approximately 5% percent of breast cancer patients but numerous studies have shown that they have a worse prognosis and poorer outcome than women diagnosed at older ages. Breast tumors from young women are often ER-negative, from African-American patients and have other indicators of high risk: yet, multivariate analyses demonstrated that young age, in and of itself, is an independent predictor of poor outcome. At least partially due to the unique nature of the patient population served by DOD, a disproportionate number of breast cancer cases in young women are seen at Walter Reed National Military Medical Center. Thus CBCP has enrolled a good number of invasive breast cancer patients under 40 making it possible for us to propose this study. The CBCP Tissue Bank hosted at the Windber Research Institute has ~40 tumors in OCT with germ line DNA available from blood clots for these sample. Thus there are sufficient numbers to get meaningful data. The tumors from young patients will be directly compared to those in the biobank from older women using the same platforms. The tumors have undergone whole exome sequencing, RNAseq, and proteomic analysis. This work has identified molecular differences in tumors from young women compared to older women. The work is currently being prepared for publication. 2) The phase I portion of the clinical trial for the metaplastic patients is ongoing at Methodist Hospital and one the recommended phase II dose is established, we will open the phase II study at the NIH Clinical Center. 3) Preclinical studies in vitro and in animal models of EGFR amplified breast cancer are ongoing.